Aster DM Healthcare to acquire remaining 13% stake in Aster Aadhar Hospital

The 254-bed Aster Adhaar Hospital in Kolhapur has received NABH (National Accreditation Board for Hospitals and Healthcare Providers) accreditation

Aster Aadhar Hospital
Aneeka Chatterjee Bengaluru
2 min read Last Updated : Nov 27 2024 | 6:48 PM IST
Aster DM Healthcare, a Bengaluru-based hospital chain, has agreed to acquire the remaining 13 per cent stake in Aster Aadhar Hospital, formerly Prerana Hospital, in Kolhapur, Maharashtra, increasing its ownership in the health facility to 100 per cent.
 
The acquisition will be completed in two phases, with an expected completion date of December 31, 2025. This full acquisition of Prerana Hospital Limited marks a key milestone in Aster DM Healthcare’s growth and diversification strategy, further solidifying its presence in the healthcare sector.
 
The subsidiary will operate and leverage the parent company's strengths, including its established market presence and financial stability, to consolidate growth and capture new opportunities, according to the company. The 254-bed hospital has got the NABH accreditation.
 
“The complete acquisition aligns perfectly with our strategic goals to consolidate our presence in Western India. The expansion will also further build our customer base and deliver greater value to all stakeholders. The Aster Aadhar Hospital is a key step in accelerating our growth and innovation in healthcare in this region especially in the wake of significant competitive presence of healthcare establishments here,” Azad Moopen, founder & chairman of Aster DM Healthcare said.
 
Aster DM Healthcare said that it is strategically positioned to capitalise on the growing demand for advanced healthcare in India. From FY25 to FY29, the company’s India business is projected to achieve a year-on-year compound annual growth rate (CAGR) of approximately 18 per cent-20 per cent, driven by higher occupancy rates and capacity expansion. Additionally, the operating earnings before interest, tax, depreciation and amortisation (Ebitda) margin is expected to reach around 23 per cent-25 per cent over the next 4-5 years, reflecting robust growth and operational efficiency.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Aster DM Healthcarehealthcareacquisition

First Published: Nov 27 2024 | 6:00 PM IST

Next Story